Flavopiridol (Alvocidib)
别名: NSC 649890, HMR-1275, L86-8275
中文名称:夫拉平度
目录号:S1230 Purity: 99.92%
Flavopiridol (Alvocidib)与ATP竞争性抑制CDKs,包括CDK1、CDK2、CDK4、CDK6和CDK9的IC50范围为20-100 nM。作用于CDK1、2、4、6、9比作用于CDK7更具有选择性。Flavopiridol最初被发现能抑制EGFR和PKA。Flavopiridol可诱导自噬和内质网应激反应。Flavopiridol可阻滞HIV-1的复制。Phase 1/2。
CAS: 146426-40-6
客户使用Selleck的Flavopiridol (Alvocidib)发表文献135篇
- Nat Genet, 2023 55(10):1721-1734
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Nature, 2021 592(7856):789-793
- Nature, 2020 580(7801):147-150
- Signal Transduct Target Ther, 2020 26;5:17
- Signal Transduct Target Ther, 2020 26;5(1):17
- Nat Med, 2019 25(2):292-300
- Cell Res, 2019 29(9):725-738
- Gut, 2017 66(8):1358-1368
- Nat Med, 2015 10.1038/nm.3855
- Nat Commun, 2024 15(1):5151
- Nat Commun, 2024 15(1):8539
- Nat Commun, 2024 15(1):35
- Cell Rep, 2024 43(11):114964
- Cell Rep, 2024 43(11):114877
- Cell Rep, 2024 43(5):114176
- Elife, 2024 13e80684
- EMBO Rep, 2024 25(5):2188-2201
- iScience, 2024 27(7):110180
- J Cell Mol Med, 2024 28(9):e18374
- Sci Rep, 2024 14(1):7200
- PLoS One, 2024 19(10):e0311367
- bioRxiv, 2024 2024.11.15.623791
- Res Sq, 2024 rs.3.rs-5451391
- bioRxiv, 2024 2024.05.03.592391
- Sci Transl Med, 2023 15(694):eabn9674
- Nucleic Acids Res, 2023 gkad172
- Nucleic Acids Res, 2023 51(19):10484-10505
- Cell Rep, 2023 42(4):112364
- Int J Biol Macromol, 2023 258(Pt 1):128776
- Breast Cancer Res, 2023 25(1):51
- iScience, 2023 26(9):107581
- Mol Cell Biol, 2023 43(1):1-21
- bioRxiv, 2023 10.1101/2023.04.03.535285
- Nat Cardiovasc Res, 2023 2(2):112-125
- Nat Cardiovasc Res, 2023 2(6):550-571
- Nat Commun, 2022 13(1):2666
- Nat Commun, 2022 13(1):6323
- Mol Cell, 2022 S1097-2765(22)00114-9
- Autophagy, 2022 1-19
- Clin Cancer Res, 2022 clincanres.3523.2021
- J Immunother Cancer, 2022 10(9)e005116
- Cell Rep, 2022 38(11):110519
- Cell Rep, 2022 39(5):110789
- iScience, 2022 25(10):105068
- Cancer Sci, 2022 113(12):4092-4103
- Cancers (Basel), 2022 14(6)1575
- Transl Oncol, 2022 16:101323
- Front Mol Neurosci, 2022 15:881933
- Toxicol Appl Pharmacol, 2022 437:115886
- Cardiovasc Drugs Ther, 2022 10.1007/s10557-021-07285-w
- Animal Model Exp Med, 2022 10.1002/ame2.12282
- Nat Commun, 2021 12(1):808
- Nat Commun, 2021 12(1):3158
- J Control Release, 2021 333:246-257
- Curr Biol, 2021 S0960-9822(21)01411-1
- Cell Rep, 2021 36(3):109394
- J Cell Biol, 2021 220(7)e202008146
- Genome Res, 2021 31(6):981-994
- PLoS Pathog, 2021 17(4):e1009567
- Biomolecules, 2021 11(6)781
- Cancers (Basel), 2021 13(14)3418
- Pharmaceuticals (Basel), 2021 14(7)598
- J Cell Sci, 2021 134(24)jcs259237
- J Clin Haematol, 2021 2(2):48-61
- Mol Cell, 2020 7;S1097-2765(20)30269-0
- J Clin Invest, 2020 134132
- Nucleic Acids Res, 2020 24;gkaa268
- Dev Cell, 2020 55(6):707-722.e9
- EMBO Mol Med, 2020 e11099
- Cell Rep, 2020 7;31(1):107485
- Cell Signal, 2020 67:109508
- Viruses, 2020 12(10)E1067
- Int J Parasitol Drugs Drug Resist, 2020 14:167-182
- BMC Cancer, 2020 20(1):984
- PLoS One, 2020 15(9):e0239315
- bioRxiv, 2020 2020/9/20.4.7.30734
- Mol Cell, 2019 73(4):670-683.e12
- Mol Cell, 2019 74(4):651-663.e8
- Nucleic Acids Res, 2019 47(8):3921-3936
- Dev Cell, 2019 49(3):425-443
- EMBO J, 2019 38(19):e101704
- Cancer Res, 2019 79(19):5088-5101
- Cancer Res, 2019 79(9):2208-2219
- Proc Natl Acad Sci U S A, 2019 116(26):12986-12995
- Cell Chem Biol, 2019 26(1):121-130
- PLoS Pathog, 2019 15(3):e1007667
- Lab Invest, 2019 99(5):612-624
- Sci Rep, 2019 9(1):17369
- J Cell Sci, 2019 132(18)jcs233379
- Sci Adv, 2019 5(6):eaaw3593
- J Vis Exp, 2019 (151)
- Electronic Thesis and Dissertation Repository, 2019
- J Exp Med, 2018 215(12):3194-3212
- J Exp Med, 2018 215(12):3115-3135
- Br J Cancer, 2018
- Oncogene, 2018 37(28):3763-3777
- Elife, 2018 7e40228
- Sci Signal, 2018 11(530)
- Cell Oncol (Dordr), 2018 41(6):663-675
- Oncotarget, 2018 9(100):37352-37366
- Oncotarget, 2018 9(34):23505-23518
- Oncotarget, 2018 9(5): 6174–6187
- Oncotarget, 2018 9(9):8560-8572
- EMBO J, 2017 36(2):202-212
- Cell Biosci, 2017 7:43
- Oncotarget, 2017 8(68):112313-112329
- Oncotarget, 2017 8(35):59476-59491
- Onco Targets Ther, 2017 10:439-446
- PLoS One, 2017 12(5):e0177871
- Clin Cancer Res, 2016 22(10):2555-64
- Cancer Res, 2016 76(5):1158-69
- Mol Cell Proteomics, 2016 15(10):3203-3219
- Aging (Albany NY), 2016 8(2):366-81
- Cell Cycle, 2016 15(20):2780-91
- Trop Life Sci Res, 2016 27(supp1):125-130
- Nat Commun, 2015 6:8481
- Leukemia, 2015 10.1038/leu.2015.99
- Antimicrob Agents Chemother, 2015 59(4):2062-71
- Sci Rep, 2015 5:10120
- Front Neural Circuits, 2015 9:63
- Cancer Chemother Pharmacol, 2015 76(1):105-16
- Water Res, 2014 61:67-76
- Leukemia, 2014 28(3):629-41
- Front Cell Neurosci, 2014 8:39
- ACS Chem Biol, 2014 10.1021/cb500072z
- PLoS One, 2014 9(10):e111146
- Nucl Med Biol, 2014 41(10):856-62
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Int J Cancer, 2013 133(10):2341-50
- Cell Cycle, 2013 12(23):3689-701
- PLoS One, 2013 8(12):e83467
- Mol Cancer Ther, 2012 11(11):2321-30
- P Natl Acad Sci USA, 2011 108(20):8414-9
- Mol Cancer Ther, 2011 10(9):1624-34
化学信息&溶解度
分子量 | 401.84 |
分子式 | C21H20ClNO5 |
CAS号 | 146426-40-6 |
Smiles | CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 80 mg/mL ( 199.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 80 mg/mL ( 199.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
30%PEG300
65%ddH2O
浓度:2.5mg/ml
(6.22mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到300μL PEG 300中,混合均匀使其澄清;然后继续加入650μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。